Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...
The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two ...
Roche (RHHBY) (RHHBF) has reiterated its plans to continue clinical trials for its anti-myostatin antibody emugrobart (GYM329/RO7204239) in obesity despite mid-stage trial setbacks for the candidate ...
Carlos Romero, right, with Linda Taylor, left, and Noah Linsky, center, who supported Romero when he competed in the ParaClimbing World Championship. Romero, who was diagnosed with facioscapulohumeral ...
Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Facioscapulohumeral Muscular Dystrophy - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering The "Facioscapulohumeral Muscular ...
The FSH Society, a Massachusetts-based charity that focuses on the incurable disease facioscapulohumeral muscular dystrophy, recently announced the launch of its #CureFSHD campaign. The purpose of the ...
Mutations in genes that modify DNA packaging result in facioscapulohumeral muscular dystrophy (FSHD)
University of Washington. "Mutations in genes that modify DNA packaging result in facioscapulohumeral muscular dystrophy (FSHD)." ScienceDaily. ScienceDaily, 11 November 2012. <www.sciencedaily.com / ...
A new paper details success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results